The shares of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) has been pegged with a rating of Neutral by B. Riley FBR in its latest research note that was published on February 27th, 2019. The research company has also assigned a $45 price target. B. Riley FBR wasn’t the only research firm that published a report of Health Insurance Innovations, Inc., with other equities research analysts also giving their opinion on the stock. Lake Street advised investors in its research note published on October 31st, 2018, to Buy the HIIQ stock while also putting a $75 price target. The stock had earned Strong Buy rating from First Analysis Sec when it published its report on October 29th, 2018. That day the First Analysis Sec set price target on the stock to $65. The stock was given Outperform rating by Raymond James in its report released on March 1st, 2018. B. Riley FBR, Inc. was of a view that HIIQ is Buy in its latest report on February 13th, 2018 while giving it a price target of $38. Raymond James thinks that HIIQ is worth Mkt Perform rating. This was contained in the firm’s report on June 26th, 2017.

Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 1 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $65.88. The price of the stock the last time has raised by 54.87% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 40.79.

The shares of the company added by 5.54% during the trading session on Thursday, reaching a low of $31.3 while ending the day at $33.53. During the trading session, a total of 2.31 million shares were traded which represents a -115.56% decline from the average session volume which is 1.07M shares. HIIQ had ended its last session trading at 31.77. Health Insurance Innovations, Inc. currently has a market cap of $551.23M, while its P/E ratio stands at 34.93, while its P/E earnings growth sits at 1.57, with a beta of 1.75. Health Insurance Innovations, Inc. debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at . HIIQ 52-week low price stands at $21.65 while its 52-week high price is $63.13.

The company in its last quarterly report recorded $0.98 earnings per share which is above the $0.77 predicted by most analysts. The Health Insurance Innovations, Inc. generated $131.92 million in revenue during the last quarter, which is slightly higher than the $83.12 million predicted by analysts. In the second quarter last year, the firm recorded $0.61 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 37.76%. Health Insurance Innovations, Inc. has the potential to record 0.96 EPS for the current fiscal year, according to equities analysts.

Investment analysts at Barclays published a research note on May 21st, 2018 where it informed investors and clients that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is now rated as Equal Weight. Their price target on the stock stands at $5. Lake Street also rated ACHN as Reiterated on October 31st, 2018, with its price target of $75 suggesting that ACHN could surge by 45.27% from its current share price. Even though the stock has been trading at $3.04/share, analysts expect it to surge higher by -0.99% to reach $5.50/share. It started the day trading at $3.12 and traded between $2.935 and $3.01 throughout the trading session.

A look at its technical shows that ACHN’s 50-day SMA is 2.34 while its 200-day SMA stands at 2.78. At the moment, only of Achillion Pharmaceuticals, Inc. shares were sold short. The company’s average trading volume currently stands at 2.61M shares, which means that the short-interest ratio is just 5.81 days. Over the past seven days, the company moved, with its shift of 13.16%. Looking further, the stock has dropped -1.31% over the past 90 days while it lost -9.34% over the last six months.

The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. RTW Investments LP bought more ACHN shares, increasing its portfolio by +1.13% during the last quarter. This move now sees RTW Investments LP purchasing 153,679 shares in the last quarter, thus it now holds 13,749,383 shares of ACHN, with a total valuation of $34,510,951. BlackRock Fund Advisors meanwhile bought more ACHN shares in the recently filed quarter, changing its stake to $27,323,697 worth of shares. The Vanguard Group Inc followed the path by decreasing its ACHN portfolio by -26.72% in the quarter. This means that The Vanguard Group Inc sold -3,096,015 shares in the last quarter and now controls 8,488,811 shares of the ACHN stock, with the valuation hitting $21,306,916.

Similarly, Citadel Advisors LLC increased its Achillion Pharmaceuticals, Inc. shares by +31.42% during the recently filed quarter. After buying 1,311,839 shares in the last quarter, the firm now controls 5,487,094 shares of Achillion Pharmaceuticals, Inc. which are valued at $13,772,606. In the same vein, Goldman Sachs Co LLC increased its Achillion Pharmaceuticals, Inc. shares by during the most recent reported quarter. The firm bought 675,630 shares during the quarter which increased its stakes to 5,321,046 shares and is now valued at $13,355,825. Following these latest developments, around 0.15% of Achillion Pharmaceuticals, Inc. stocks are owned by institutional investors and hedge funds.